EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Newsletter

What should be completed by November 20?

Dose Diligence research deskSection 10 · Page 2 of 15Last updated 17 Nov 2026

Proposed internal deadlines—not regulatory deadlines.

OwnerDeliverableEvidence of completion
Medical directorReview the FDA safety communicationApproved patient-message and escalation changes
COOClassify recent interrupted-access casesSeparate operational, affordability and clinical categories
Compliance leadCorrect the DSCSA register where applicableDocumented entity-level exemption assessment
CFOAudit promotional-price assumptionsIntroductory and continuing costs shown separately
ProcurementChallenge the largest partner’s fallback planNamed alternative, acceptance criteria and escalation contact

Take to the next procurement meeting: one anonymised failed order, one current patient-price example and one supplier compliance assertion that still lacks evidence.

This briefing supports procurement decisions; it does not authorise a supply route or recommend treatment changes.

Explore the table row by row

A working view of the research

Medical director

Deliverable
Review the FDA safety communication
Evidence of completion
Approved patient-message and escalation changes

Sources cited on this page

    See the section’s source register for the research context.

    Section sources →